Bivalirudin (CAS 128270-60-0) is a high-purity direct thrombin inhibitor (DTI) API, designed for anticoagulation therapy. With a precise 20-amino acid peptide structure, it acts as a potent, specific inhibitor of thrombin, the key enzyme in the coagulation cascade. By binding to the active site of thrombin, Bivalirudin effectively blocks its ability to convert fibrinogen to fibrin and to activate platelets, thereby preventing the formation of blood clots.
Produced under strict GMP standards, this API ensures consistent purity (≥98%) and biological activity, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for the treatment of acute coronary syndrome (ACS), including unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), as well as for anticoagulation during percutaneous coronary intervention (PCI). It is also used in cardiopulmonary bypass surgery.
Its unique mechanism of action, which does not require anti-Xa factor monitoring, makes it a preferred choice for clinical use. Bivalirudin provides reliable anticoagulation with a favorable safety profile, catering to the needs of pharmaceutical manufacturers and research institutions in cardiovascular medicine.
